MedPath
Found 3 clinical trials|View Analysis
Sort by:

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Phase 1
Terminated
Conditions
Pancreas Cancer
HRD Positive Advanced Ovarian Cancer
Breast Cancer
Ovarian Cancer
BRCA1 Mutation
Prostate Cancer
BRCA-Mutated Ovarian Carcinoma
BRCA-Associated Breast Carcinoma
Interventions
Drug: TNG348
Drug: Olaparib
First Posted Date
2023-10-03
Last Posted Date
2024-08-13
Lead Sponsor
Tango Therapeutics, Inc.
Target Recruit Count
7
Registration Number
NCT06065059
Locations
๐Ÿ‡บ๐Ÿ‡ธ

New York University Langone Health, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mid Florida Cancer Centers, Orange City, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Florida Cancer Specialists, Sarasota, Florida, United States

and more 4 locations

Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation

Recruiting
Conditions
BRCA-Associated Breast Carcinoma
Interventions
Genetic: Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
First Posted Date
2023-03-10
Last Posted Date
2023-03-10
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Target Recruit Count
10
Registration Number
NCT05763472
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, RM, Italy

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Phase 2
Recruiting
Conditions
Triple Negative Breast Neoplasms
Triple Negative Breast Cancer
Breast Neoplasms
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
BRCA Mutation
BRCA-Associated Breast Carcinoma
Interventions
First Posted Date
2022-08-03
Last Posted Date
2024-02-13
Lead Sponsor
Okayama University
Target Recruit Count
23
Registration Number
NCT05485766
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

St. Luke's International Hospital, Tokyo, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Aichi Cancer Center, Nagoya, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Okayama University Hospital, Okayama, Japan

ยฉ Copyright 2025. All Rights Reserved by MedPath